Leukemia, Myeloid, Acute: all 3,035 studies
Page 23 of 31. Open to participants first (746), then studies with results posted, then the rest; newest registration first within each.
- Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior TransplantationActive, not recruitingNCT02790515Phase 2
- FLYSYN in MRD Positive AMLCompletedNCT02789254Phase 1/2
- A Safety Study of Human Cord Blood Derived, Culture Expanded Natural Killer Cell (PNK-007) Infusion With Subcutaneous Recombinant Human IL-2 (rhIL-2) in Adults With Relapsed and/or Refractory Acute Myeloid Leukemia (AML)TerminatedNCT02781467Phase 1
- Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic LeukemiaCompletedNCT02779283Phase 1
- NK Cells as Consolidation Therapy of Acute Myeloid Leukemia in Children/AdolescentsCompletedNCT02763475Phase 2
- Haploidentical Hematopoietic Stem Cell Transplantation for Acute LeukemiasStatus unknownNCT02759822
- Prophylactic Application of Donor-derived TCM After Allogeneic HSCTCompletedNCT02758223Phase 1/2
- Improving Risk Assessment of AML With a Precision Genomic Strategy to Assess Mutation ClearanceActive, not recruitingNCT02756962Phase 2
- Peptide Vaccination in Combination With Azacitidine for Patients With MDS and AMLCompletedNCT02750995Phase 1
- Study of IRX5183 in Relapsed and Refractory Acute Myeloid Leukemia and High Risk Myelodysplastic SyndromeTerminatedNCT02749708Phase 1
- A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With AML or MDSCompletedNCT02732184Phase 1
- PH 1 Study to Evaluate Safety and Tolerability of XmAb14045 in Patients With CD123-expressing Hematologic MalignanciesCompletedNCT02730312Phase 1
- Sirolimus and Mycophenolate Mofetil in Preventing GVHD in Patients With Hematologic Malignancies Undergoing HSCTTerminatedNCT02728700Phase 1
- International Randomised Phase III Clinical Trial in Children With Acute Myeloid LeukaemiaActive, not recruitingNCT02724163Phase 3
- Midostaurin in Treating Older Patients With Mutated Acute Myeloid Leukemia Post-TransplantWithdrawnNCT02723435Phase 2
- A Study to Find a Safe Dose of Volasertib Given in Addition to Standard Salvage Chemotherapy in Children (Age 3 Months to Less Than 18 Years) With Acute Myeloid Leukaemia, in Whom Front-line Chemotherapy FailedWithdrawnNCT02722135Phase 1
- Study of Sensitization of Non-M3 AML Blasts to ATRA by Epigenetic Treatment With Tranylcypromine (TCP)Status unknownNCT02717884Phase 1/2
- Dose Escalation Study of JNJ-63709178, a Humanized CD123 x CD3 DuoBody in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)CompletedNCT02715011Phase 1
- Prognostic Role of Minimal Residual Disease in Acute Myeloid LeukemiaCompletedNCT02714790
- Decitabine for Chemotherapy Unfit Korean AML Patients in Real PracticeStatus unknownNCT02698124
- Clofarabine, Cytarabine and Mitoxantrone (CLAM) for Relapsed or Refractory AMLCompletedNCT02686593Phase 2
- A Study of PLX51107 in Advanced MalignanciesTerminatedNCT02683395Phase 1
- Molecular Imaging to Capture Disease Heterogeneity in Acute Myeloid LeukemiaStatus unknownNCT02682732Not applicable
- Dasatinib in Combination With Chemotherapy for Relapsed or Refractory Core Binding Factor Acute Myeloid LeukemiaWithdrawnNCT02680951Phase 1
- Hematopoietic Stem Cell Microtransplantation for in AMLStatus unknownNCT02676856Not applicable
- Panobinostat With Fludarabine and Cytarabine for Treatment of Children With Acute Myeloid Leukemia or Myelodysplastic SyndromeTerminatedNCT02676323Phase 1
- Open-label Study of IMGN779 in Adult Patients With Relapsed/Refractory CD33-positive Acute Myeloid LeukemiaCompletedNCT02674763Phase 1
- IDA+BUCY vs BUCY Conditioning Regimen for Intermediate-risk AML Undergoing Auto-HSCTCompletedNCT02671708Phase 2/3
- A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic TherapyCompletedNCT02670044Phase 1
- Samples From Leukemia Patients and Their Donors to Identify Specific AntigensStatus unknownNCT02667093
- Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid LeukemiaActive, not recruitingNCT02665065Phase 3
- Investigating the Relationship Between Physical Function, Comorbidity and Cytogenetic Risk Group in Older Adults With Acute Myelogenous Leukemia (AML)CompletedNCT02662933Not applicable
- Investigating the Prevalence and Prognostic Importance of Polypharmacy in Adults Treated for Newly Diagnosed Acute Myelogenous Leukemia (AML)CompletedNCT02662920
- Allo HSCT Using RIC for Hematological DiseasesCompletedNCT02661035Phase 2
- LY2510924, Idarubicin and Cytarabine in Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT02652871Phase 1
- Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer IndicationsCompletedNCT02649790Phase 1/2
- Prexasertib (LY2606368), Cytarabine, and Fludarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeCompletedNCT02649764Phase 1
- A Study of CC-90002 in Subjects With Acute Myeloid Leukemia (AML) and High-risk Myelodysplastic Syndrome (MDS)TerminatedNCT02641002Phase 1
- Ibrutinib, Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaTerminatedNCT02635074Phase 1
- Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 MutationActive, not recruitingNCT02632708Phase 1
- Phase I Study of Mitoxantrone and Etoposide Combined With Hydroxychloroquine, for Relapsed Acute Myelogenous LeukemiaTerminatedNCT02631252Phase 1
- Midostaurin Access Program for Newly Diagnosed FLT3 (ITD or TKD) Mutated AML Adult Patients Eligible for Standard Induction and Consolidation ChemotherapyNo longer availableNCT02624570
- CD123 Redirected Autologous T Cells for AMLTerminatedNCT02623582Early Phase 1
- ChEmo-Genomics Based Treatment of Acute Myeloid LeukemiaStatus unknownNCT02619071Not applicable
- A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Doses of AGS67E Given as Monotherapy in Subjects With Acute Myeloid Leukemia (AML)TerminatedNCT02610062Phase 1
- Study of Dendrogenin A / Oxysterols Balance Between Healthy Volunteers and Acute Myeloid Leukemia PatientsCompletedNCT02602587Not applicable
- Donor Cellular Therapy After Cytarabine in Treating Patients With Intermediate-Risk Acute Myeloid Leukemia in RemissionWithdrawnNCT02587871Phase 2
- MLN 9708 in Induction and Consolidation for Adults With AML >= 60 Years of AgeCompletedNCT02582359Phase 1
- Metabolic Changes in Blood Samples From Patients With Acute Myeloid LeukemiaCompletedNCT02581917
- Dose Escalation of OXi4503 as Single Agent and Combination With Cytarabine w/Subsequent Ph 2 Cohorts for AML and MDSStatus unknownNCT02576301Phase 1/2
- Lintuzumab-Ac225 in Older Acute Myeloid Leukemia (AML) PatientsCompletedNCT02575963Phase 1/2
- Selinexor With Combination Chemotherapy in Treating Patients With Acute Myeloid LeukemiaCompletedNCT02573363Phase 1
- Stem Cell Transplantation From HLA Partially-Matched Related Donors for Patients With Hematologic MalignanciesCompletedNCT02566395Phase 3
- A Phase I/II Study of Gene-modified WT1 TCR Therapy in MDS & AML PatientsCompletedNCT02550535Phase 1/2
- Study Evaluating the Safety and Efficacy of Astarabine in Acute Myeloid Leukemia or Acute Lymphoblastic LeukemiaCompletedNCT02544438Phase 1/2
- Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic MalignanciesCompletedNCT02543879Phase 1
- Hu8F4 in Treating Patients With Advanced Hematologic MalignanciesActive, not recruitingNCT02530034Phase 1
- Ruxolitinib Phosphate, Tacrolimus and Sirolimus in Preventing Acute Graft-versus-Host Disease During Reduced Intensity Donor Hematopoietic Cell Transplant in Patients With MyelofibrosisWithdrawnNCT02528877Phase 1
- Biomarkers for Personalized Early Assessment of Response During Salvage Chemotherapy in People With Relapsed or Refractory Acute Myeloid Leukemia (PEARL15)CompletedNCT02527447
- A Study of Volasertib Plus Induction Chemotherapy for Acute Myeloid LeukemiaWithdrawnNCT02527174Phase 1
- Pilot Study Immunomonitoring Natural Killers Cells in Patients With Myeloid Malignancies Treated With LenalidomideCompletedNCT02525250Not applicable
- Open Label Study of Sargramostim Among Patients Receiving Myelosuppressive Induction Chemotherapy for Acute Myelogenous LeukemiaWithdrawnNCT02520102Phase 2
- Administration of Donor Multi TAA-Specific T Cells for AML or MDS (ADSPAM)CompletedNCT02494167Phase 1
- B7.1/IL-2 Leukaemia Cell Vaccine for Non-Transplant AML RFUSIN2-AML2 (NTX)Status unknownNCT02493829Phase 1
- Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1 and/or IDH2 MutationCompletedNCT02492737Phase 1
- Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After TransplantCompletedNCT02485535Phase 1
- A Study of (Interleukin-12) IL-12 in Patients With Acute Myelogenous Leukemia (AML)Active, not recruitingNCT02483312Phase 1
- Randomized Study of Haploidentical Hct and Subsequent Donor nk Cell Infusion in High-risk AML and MDSTerminatedNCT02477787Phase 2
- Sorafenib for Prophylaxis of Leukemia Relapse in Allo-HSCT Recipients With FLT3-ITD Positive AMLCompletedNCT02474290Phase 2/3
- Azacitidine, Lenalidomide and DLI as Salvage Therapy for MDS, CMML and sAML Relapsing After Allo-HSCTCompletedNCT02472691Phase 2
- 6,8-Bis(Benzylthio)Octanoic Acid, Cytarabine, and Daunorubicin Hydrochloride in Treating Older Patients With Newly Diagnosed Acute Myeloid LeukemiaWithdrawnNCT02472626Phase 1/2
- Oshadi D & Oshadi R Combined With Salvage Chemotherapy for Relapsed Acute Myeloid Leukemia or Lymphoid Leukemia PatientsSuspendedNCT02462265Phase 2
- HLA-mismatched MST vs HLA-matched NST for AML in Intermediate-riskCompletedNCT02461121Phase 3
- A Study of Safety, Efficacy and Pharmacodynamics of Azacitidine in Children and Young Adults With Acute Myeloid Leukemia.CompletedNCT02450877Phase 2
- Total Marrow and Lymphoid Irradiation and Chemotherapy Before Donor Transplant in Treating Patients With Myelodysplastic Syndrome or Acute LeukemiaCompletedNCT02446964Phase 1
- PF-05212384 (PKI-587) for t-AML/MDS or de Novo Relapsed or Refractory Acute Myeloid Leukemia (AML) (LAM-PIK)TerminatedNCT02438761Phase 2
- iCare for Cancer PatientsTerminatedNCT02435550Not applicable
- Treatment of Elderly Chinese Acute Myeloid Leukemia Patients Aged 65 to 75 Years OldStatus unknownNCT02432911Not applicable
- Treatment of Older Adult Acute Myeloid Leukemia Patients Aged 55 to 65 YearsStatus unknownNCT02432872Not applicable
- Granulocyte Colony Stimulating Factor (G-CSF) After Salvage Chemotherapy in Refractory AMLStatus unknownNCT02427919Phase 2/3
- The Effect of Deferasirox on Response Rate of Acute Leukemia Patients Not Treated by Standard Chemotherapy RegimensStatus unknownNCT02413021Phase 1
- Epigenetic Reprogramming in Relapse AMLTerminatedNCT02412475Phase 1
- DC Vaccination for Post-remission Therapy in AMLCompletedNCT02405338Phase 1/2
- A Study of Selinexor in Combination With Daunorubicin and Cytarabine for Untreated AMLCompletedNCT02403310Phase 1
- ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic SyndromeTerminatedNCT02392572Phase 1/2
- A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With CancerCompletedNCT02391480Phase 1
- CINC424A2X01B Rollover ProtocolActive, not recruitingNCT02386800Phase 4
- A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 MutationsActive, not recruitingNCT02381886Phase 1
- Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid LeukemiaTerminatedNCT02381548Phase 1
- Evaluation of Adverse Long-term Effects in Young Adult Survivors of Acute LeukemiaStatus unknownNCT02345915Not applicable
- A Pilot RCT of the PRISM Intervention for AYAs With CancerCompletedNCT02340884Phase 2
- Natural History and Biology of Long-Term Late Effects Following Hematopoietic Cell Transplant for Childhood Hematologic MalignanciesStatus unknownNCT02338479
- Memory T-cell Infusion to Improve Immunity After TCR-alpha/Beta Depleted Hematopoietic Stem Cell TransplantationCompletedNCT02337595Phase 1/2
- First-in-Human Study of FLX925 in Subjects With Relapsed or Refractory Acute Myeloid LeukemiaTerminatedNCT02335814Phase 1
- Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell TransplantSuspendedNCT02333162Phase 1
- Treosulfan-based Conditioning in Paediatric Patients With Haematological MalignanciesCompletedNCT02333058Phase 2
- A 5 Day Course of Fludarabine and Cytarabine Followed by Full Intensity Allogeneic Stem Cell Transplantation (FA5-Bucy) in Treating Patients With High-risk, Recurrent or Refractory Acute Leukemia and Advanced Myelodysplastic SyndromeStatus unknownNCT02328950
- A Safety Study of SGN-CD33A in Combination With Standard-of-care in Patients With AMLCompletedNCT02326584Phase 1
- Pacritinib and Chemotherapy in Treating Patients With Acute Myeloid Leukemia and FLT3 MutationsCompletedNCT02323607Phase 1
- Idarubicin Plus Cytarabine (IA) vs IA Plus Cladribine (IAC) as Induction Regimen to Treat Initially Diagnosed Acute Myeloid Leukemia (AML)CompletedNCT02323022Phase 3